MAI Capital Management’s Annovis Bio ANVS Stock Holding History

MAI Capital Management’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$1.11K	–	2221
2026 Q1	$1.11K	Buy	+500	New	+$1.37K	﹤0.01%	4140

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MAI Capital Management's ANVS Position: Q2 2026 in Review

MAI Capital Management sold out of Annovis Bio (ANVS) in Q2 2026, closing a stake of 500 shares — an estimated $1.11K sold.

MAI Capital Management first reported a position in ANVS in Q1 2026 and held it in 1 quarter. The position peaked at $1.11K in Q1 2026. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

MAI Capital Management reported no remaining Annovis Bio position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 500 Annovis Bio shares in Q2 2026, an estimated $1.11K.
MAI Capital Management first reported a position in Annovis Bio in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Annovis Bio position peaked at $1.11K in Q1 2026.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.